Thermo Fisher Scientific

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future. 

News items for the in vitro diagnostics industry for the week of Nov. 2, 2020.

Thermo Fisher's transplant diagnostics products include antibody detection assays, post-transplant monitoring solutions, HLA typing products, and lab instrumentation.

The company reported net income of $1.93 billion, or $4.84 per share, compared to $760 million, or $1.89 per share, for the year-ago quarter.

Thermo Fisher's test is now authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens.

One of the tests, the OmniPath COVID-19 Total Antibody ELISA Test, has already received Emergency Use Authorization from the US Food and Drug Administration.